The GSTM3 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to abolish GSTM3 gene function in the HeLa background through targeted gene disruption. This polyclonal format preserves a heterogeneous mixture of edited alleles, offering a genetically diverse loss-of-function model without clonal selection. By eliminating GSTM3 expression, these cells enable systematic investigation of glutathione S-transferase mu 3-dependent processes in a widely utilized human cell line.
The parental HeLa cell line is an immortalized epithelial cell derived from a cervical adenocarcinoma and carries integrated human papillomavirus 18 (HPV18) sequences. Established in 1951 from a tumor biopsy of Henrietta Lacks, HeLa cells represent the first continuously cultured human cell line and have become a cornerstone of biomedical research. Their aneuploid karyotype and robust proliferation make them a versatile host for gene-editing applications, particularly in cancer biology and signal transduction studies.
GSTM3 encodes a phase II detoxification enzyme that catalyzes the conjugation of reduced glutathione (GSH) to electrophilic xenobiotics, facilitating their elimination. Beyond its enzymatic function, GSTM3 directly interacts with apoptosis signal-regulating kinase 1 (ASK1, also known as MAP3K5) to inhibit oxidative stress-induced MAP kinase signaling. This binding suppresses downstream phosphorylation of MKK4/MKK7 and reduces JNK/p38 activation, thereby limiting apoptosis and pro-inflammatory cytokine production. Transcription of GSTM3 is controlled by the transcription factor NFE2L2 (Nrf2), which binds antioxidant response elements (ARE) in the promoter upon activation by oxidative or electrophilic stress, forming a NFE2L2/KEAP1/ARE regulatory axis.
In the HeLa context, disruption of GSTM3 provides a powerful tool to dissect redox-dependent signaling networks and chemoresistance mechanisms. Loss of GSTM3-dependent ASK1 inhibition is expected to sensitize cells to oxidative stress and genotoxic agents, while also altering basal MAPK pathway activity. This makes the knockout model particularly relevant for studying the molecular determinants of carcinogenesis and therapeutic response in cervical and other cancers, as well as for modeling aspects of pulmonary and neurodegenerative diseases linked to impaired detoxification.
These polyclonal GSTM3 knockout HeLa cells are suited for a range of experimental applications including detoxification pathway analysis, oxidative stress response profiling, MAP kinase signaling dissection, and drug metabolism studies. Typical assays include western blotting for pathway components, glutathione S-transferase activity measurements, reactive oxygen species (ROS) detection, apoptosis assays, co-immunoprecipitation of GSTM3 interaction partners, phospho-JNK/p38 analysis, and qPCR for NFE2L2 target genes. Researchers employing this model can interrogate the interplay between glutathione conjugation and kinase signaling in a disease-relevant epithelial system. For further details and ordering information, please contact Ascent Research.
